Cell>Point: CellPoint Plans to Complete Phase 2b Trial in Evaluating the Presence and Severity of Coronary Artery Disease

CENTENNIAL, Colo., May 17, 2019 /PRNewswire/ -- CellPoint announced today that it plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company's new one-vial Oncardia® (ethylenedicysteine-glucosamine) kits. The 60 patient trial study is being conducted in the U.S. Today, slightly greater than 6 million nuclear cardiology perfusion imaging scans are performed in the U.S. annually. Such pro...